image credit: Rawpixel

FDA sets advisory meeting date for Brainstorm’s ALS cell therapy

The Food and Drug Administration has set a date for an upcoming meeting in which an outside group of experts will evaluate an experimental ALS medicine the agency has appeared wary of approving.

The medicine’s developer, Brainstorm Cell Therapeutics, disclosed Tuesday that the meeting will take place on Sept. 27. It will focus on an approval application Brainstorm recently filed, and have representatives from the company and the FDA present their cases to a committee that advises the agency on cell, tissue and gene therapies.

Read More on Biopharma Dive